Patients with mitochondrial diseases, who usually manifest a multisystem disease, are considered potentially at-risk for a severe coronavirus disease 2019 (COVID-19). The objective of this study is to analyze the clinical features, prognosis and outcomes of COVID-19 in patients with primary mitochondrial diseases in a cohort of patients followed in Italy.

We searched for patients with primary mitochondrial diseases and COVID-19 followed by the Italian Collaborative Network of Mitochondrial Diseases. In a total of 1843 patients followed by the National Network, we have identified from March 1st to January 30th, 2021, 27 SARS-CoV-2 infection. Most of the patients were pauci or asymptomatic (85%) and treated at home. The most common signs of COVID-19 were fever (78,9%), fatigue (47,4%), myalgia (42,1%), cough and headache (36,8%), and dyspnea (31,6%). Those who required COVID-19 therapy were treated with low-molecular-weight heparin, glucocorticoids, and antibiotics (mainly azithromycin) without serious side effects related to the therapy. Five patients (18,5%) clinically deteriorated during the infection, and one of them died for pneumonia.

Primary mitochondrial diseases infected individuals seemed to be similarly affected by SARS-CoV-2 compared with the general Italian population in terms of clinical presentation and outcome.

患有线粒体疾病的患者通常表现出多系统疾病，被认为有可能患上严重的冠状病毒病 2019 (COVID-19)。本研究的目的是分析在意大利随访的一组原发性线粒体疾病患者中 COVID-19 的临床特征、预后和结果。

我们搜索了患有原发性线粒体疾病和 COVID-19 的患者，然后搜索了意大利线粒体疾病协作网络。从 2021 年 3 月 1 日到 1 月 30 日，我们在国家网络跟踪的总共 1843 名患者中确定了 27 名 SARS-CoV-2 感染者。大多数患者很少或无症状 (85%)，并在家中接受治疗。COVID-19 最常见的症状是发烧 (78.9%)、疲劳 (47.4%)、肌痛 (42.1%)、咳嗽和头痛 (36.8%) 以及呼吸困难 (31.6%) ). 那些需要 COVID-19 治疗的患者接受了低分子肝素、糖皮质激素和抗生素（主要是阿奇霉素）的治疗，没有出现与治疗相关的严重副作用。五名患者 (18.5%) 在感染期间临床症状恶化，其中一名死于肺炎。

就临床表现和结果而言，与普通意大利人群相比，原发性线粒体疾病感染者似乎同样受到 SARS-CoV-2 的影响。